ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0761

Anti-Peptidylarginine Deaminase Antibodies in the Individuals with Arthralgia at Risk of Progression to Rheumatoid Arthritis

Nora Petrovská1, Klára Prajzlerová1, Ivana Půtová2, Monika Gregová1, Petra Hánová2, Heřman Mann3, Karel Pavelka1, Jiří Vencovský1, Ladislav Šenolt1 and Mária Filková1, 1Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, 3Institute of Rheumatology, Prague, Czech Republic. Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

Meeting: ACR Convergence 2020

Keywords: Anti-citrullinated Protein Autoantibodies (ACPAs), Autoantibody(ies), autoantigens, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 7, 2020

Title: RA – Diagnosis, Manifestations, & Outcomes Poster II: Biomarkers

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: In order to identify the individuals at risk of imminent progression to rheumatoid arthritis (RA), EULAR has established a definition of clinically suspect arthralgia (CSA). Individuals carrying autoantibodies e.g. anti-citrullinated protein antibodies (ACPA) and rheumatoid factors (RF) are at high risk of developing RA. Peptidyl arginine deaminases (PAD) are enzymes responsible for producing autoantigens by citrullination of proteins and, importantly, may themselves represent as an autoantigen. Similar to ACPA and RF, anti-PAD antibodies are detectable years before the disease onset. We aimed to determine the prevalence of anti-PAD autoantibodies and their coincidence with RF and ACPA in sera of the individuals at risk-of developing RA.

Methods: Our prospective study included 86 individuals at-risk of progression to RA defined as having arthralgia without arthritis and being either ACPA+ or meeting the clinical CSA definition. Antibodies against PAD3 and PAD4 were analyzed in serum using commercially available ELISA kit (MyBioSource).

Results: Of the 86 at-risk individuals, 65 were seropositive (RF+ and/or ACPA+) and 54 met the CSA definition (33 were seropositive) with median duration of arthralgia 12 months. Of all individuals, 30 (34.8%) were anti-PAD+ (specifically, 14% were anti-PAD3+ and 21% were anti-PAD4+). Of 21 individuals who were both RF+ and ACPA+, 57% were anti-PAD+. Thirty % of RF- and 26% of ACPA- individuals were anti-PAD+. Of 21 seronegative (RF- and ACPA-) individuals, 33% were anti-PAD+. A third of individuals who met the CSA definition were anti-PAD+, irrespective of RF and ACPA positivity, 33% of seropositive CSA individuals were also anti-PAD+.

Sixteen patients progressed to RA within a median of 7.5 months of follow up with median DAS28(CRP) 2.28. Of these, 14 were RF+ and/or ACPA+ and 9 were anti-PAD+. All RF, ACPA and anti-PAD autoantibodies were positive in 5 individuals, both seronegative individuals were also anti-PAD-.

Conclusion: A third of the at-risk individuals with arthralgia, originally assessed as seronegative, were carriers of anti-PAD autoantibodies, however, none of them was both anti-PAD3 and anti-PAD4 positive. Similarly, a third of seropositive at-risk individuals were anti-PAD positive. The predictive value of anti-PAD antibodies for future development of RA in the at-risk individuals with arthralgia needs to be investigated.


Disclosure: N. Petrovská, None; K. Prajzlerová, None; I. Půtová, None; M. Gregová, None; P. Hánová, None; H. Mann, None; K. Pavelka, AbbVie, 8, Merck Sharp & Dohme, 8, Bristol-Myers Squibb Company, 8, Roche, 8, Amgen, 8, Pfizer, 8, Novartis, 8, Egis, 8, Biogen, 8, UCB, 8; J. Vencovský, Eli Lilly, 5, 8, Abbvie, 5, 8, Boehringer, 5, Octapharma, 5, Sanofi, 8, Merck, 8, Biogen, 8, UCB Biopharma, 8, Roche, 8, Pfizer, 8; L. Šenolt, AbbVie, 2, 5, 8, Amgen, 5, 8, BMS, 5, 8, Celgene, 5, 8, Eli Lilly, 8, Merck Sharp and Dohme, 5, 8, Novartis, 5, 8, Pfizer, 5, 8, Roche, 5, 8, UCB, 5, 8, Takeda, 8; M. Filková, None.

To cite this abstract in AMA style:

Petrovská N, Prajzlerová K, Půtová I, Gregová M, Hánová P, Mann H, Pavelka K, Vencovský J, Šenolt L, Filková M. Anti-Peptidylarginine Deaminase Antibodies in the Individuals with Arthralgia at Risk of Progression to Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/anti-peptidylarginine-deaminase-antibodies-in-the-individuals-with-arthralgia-at-risk-of-progression-to-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/anti-peptidylarginine-deaminase-antibodies-in-the-individuals-with-arthralgia-at-risk-of-progression-to-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology